Companies ›Healthcare ›PTEC.V

PTEC.V — TSX Venture Biotechnology & Medical Research

Principal Technologies Inc.

$0,28

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

-1 134,1 %

ROE

-4 726,4 %

Net margin

-1 143,4 %

Debt / equity

0,60

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

PTEC.V operates in the healthcare diagnostics segment, providing diagnostic solutions and related services to healthcare providers and patients.

Business. PTEC.V is a biotechnology and medical research company focused on healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, generating revenue through product sales. It is listed on the TSX Venture Exchange under the ticker PTEC.V. Specific details regarding operating segments, headquarters location, and geographic presence are not available in the provided data.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityHealthcare Diagnostics

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

-4 726,4 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning PTEC.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to PTEC.V. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

PTEC.V is a biotechnology and medical research company focused on healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, generating revenue through product sales. It is listed on the TSX Venture Exchange under the ticker PTEC.V. Specific details regarding operating segments, headquarters location, and geographic presence are not available in the provided data.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityHealthcare Diagnostics

AI synthesis

GENERATED

PTEC.V exhibits a weak capital structure and liquidity position, with a current ratio of 0.9 and a debt-to-equity ratio of 0.6. The company's total liabilities exceed its total assets, and it has a negative net cash position after subtracting total debt. Free cash flow is negative at -4189080.0 CAD, indicating a significant cash outflow from operations after capital expenditures.

Profitability metrics are severely negative, with a return on equity of -47.2643 and a return on assets of -2.7392. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating and net income are both negative, with losses of -4200850.0 CAD and -4235350.0 CAD, respectively.

The company's revenue is concentrated in a single segment, as disclosed in its financials, with no additional segment details provided. There is no geographic breakdown of revenue, making it difficult to assess the geographic exposure and potential concentration risks.

The growth trajectory of PTEC.V is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The company's historical revenue of 370420.0 CAD does not indicate a clear upward or downward trend, and the lack of detailed outlook data makes it challenging to assess future performance.

Risk factors for PTEC.V include medium liquidity risk, as indicated by the current ratio and negative free cash flow. The company has a low dilution risk, but the negative net cash position and high debt levels could pose challenges in the future. No specific dilution sources are identified in the available data.

Recent events and filings for PTEC.V are not detailed in the available data, making it difficult to assess any recent developments that may impact the company's financial position or strategic direction.

Key takeaways

PTEC.V has a weak capital structure and liquidity position, with a current ratio of 0.9 and a negative free cash flow.
The company is not generating returns for its shareholders, with a return on equity of -47.2643 and a return on assets of -2.7392.
Revenue is concentrated in a single segment, and there is no geographic breakdown of revenue.
The growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year.
The company faces medium liquidity risk and has a negative net cash position after subtracting total debt.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$0,28

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$89.6k

Net cashⓘ

-$54.1k

Current ratioⓘ

0.9

Debt / equityⓘ

0.6

ROAⓘ

-2.7%

ROEⓘ

-47.3%

Cash conversionⓘ

71.0%

CapEx / revenueⓘ

-4.0%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin-1 134,1 %Bottom quartile

Net Margin-1 143,4 %Bottom quartile

ROE-4 726,4 %Bottom quartile

Capex / Rev-4,0 %Above median

D/E0,60Bottom quartile

Cash Conv0,71Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

PTEC.V Market data — financials · 2026-05-29

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

PTEC.VCanonical

TSX Venture · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread